Hearing Against Pfizer Set For 30 May In Contraceptive ˜Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio

Pfizer is facing approximately 400 lawsuits in a U.S. multidistrict litigation concerning its Depo-Provera contraceptive injection, following a study linking the drug to a 5.6 times increased risk of intracranial meningioma in women using it for over a year. The lawsuits allege Pfizer was aware of this risk and failed to adequately warn U.S. consumers, despite issuing warnings in Canada, the UK, Europe, and South Africa; a Case Management Conference is scheduled for May 30th in Florida. Levin Papantonio, a law firm with a history of securing large settlements against major corporations, is on the Plaintiff’s Executive Committee.

Analysis

Pfizer Inc. (PFE) is confronting a significant legal challenge in the United States through a multidistrict litigation (MDL No.3140) comprising approximately 400 lawsuits. This litigation centers on its contraceptive injection, Depo-Provera, following a March 2024 British Medical Journal study which reported a 5.6-fold increased risk of intracranial meningioma for women using the product for over a year. Plaintiffs allege Pfizer was aware of this risk but failed to provide adequate warnings to U.S. consumers, contrasting with warnings issued in Canada (2015), the UK and Europe (October 2024), and South Africa (February 2025). The scale of potential impact is notable, with an estimated 74 million women globally using Depo-Provera as of 2019, and significant usage in the US (24.5% of sexually active women lifetime use) and UK (15% of women). A Case Management Conference is scheduled for May 30th. The involvement of Levin Papantonio, a law firm with a track record of securing over $80 billion in verdicts and settlements against major corporations, underscores the potential financial and reputational risk. Further studies have reportedly confirmed the meningioma risk, with one epidemiologist estimating that Depo-Provera use could increase the incidence from 40 to approximately 200 per 10,000 women. The drug, acquired by Pfizer in 2002, has a controversial history, including initial FDA approval denials due to safety concerns before its 1992 US approval. The strongly negative sentiment (-0.9 for PFE) and high market impact score (0.7) reflect the perceived severity of this situation.

Key Decisions for Investors

• Investors should closely monitor the upcoming Case Management Conference on May 30th and subsequent developments in MDL No.3140 for indications of potential financial liability and litigation trajectory for Pfizer.
• Consider the precedent of Levin Papantonio's substantial settlements against other large corporations, as this suggests a material risk of significant financial impact on Pfizer if the plaintiffs are successful.
• Evaluate the potential for an increase in litigation volume given the widespread historical usage of Depo-Provera and the severity of the alleged health risks, which could amplify financial and reputational damages.
• Assess the implications of Pfizer's inconsistent global warning standards for Depo-Provera, as the failure to warn U.S. users despite issuing warnings elsewhere could strengthen the plaintiffs' legal arguments and increase liability exposure.